Discordances in ER,PR, and HER2 between primary breast cancer and brain metastasis |
| |
Authors: | Jaehag Jung Seung Hoon Lee Mira Park Ji Hye Youn Sang Hoon Shin Ho Shin Gwak Heon Yoo |
| |
Affiliation: | 1.Department of Surgery,Eulji University Hospital,Daejeon,South Korea;2.Department of Neurosurgery,Eulji University Hospital,Daejeon,South Korea;3.Department of Preventive Medicine,Eulji University,Daejeon,South Korea;4.Neurooncology Clinic,National Cancer Center Hospital,Goyang,South Korea |
| |
Abstract: | When distant metastases are discovered, it is important to determine receptor profiles of these lesions through histologic examination. However, brain metastasis sites are difficult to reach to be routinely biopsied. The purpose of this study was to determine expression profiles of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in breast cancer brain metastasis (BCBM) and the existence of discordance between primary breast cancer and brain metastasis. A total of 37 patients who underwent craniotomies for metastatic brain tumors arising from breast cancer at National Cancer Center (NCC) of Korea between 2002 and 2014 were retrospectively reviewed. Clinicopathologic data were collected from electronic medical records. Receptor profiles of primary breast cancer and brain metastasis in each patient were identified. Data of ER, PR, and HER2 expression in brain metastasis were available in electronic medical records for 21 (56.8%) of 37 cases. Results of ER, PR, and HER2 expression were positive in 47.6, 42.9, and 38.1% of patients with brain metastasis, respectively. Receptor conversion occurred in 11 (52.4%) of 21 patients (for ER, 9.5%; for PR, 38.1%; for HER2, 23.8%). Overall survival was longer in patients with concordant receptor expression patterns between primary breast cancer and brain lesion compared to that in patients with discordant patterns. However, such difference was not statistically significant (discordant vs. concordant median survival: 19.2 versus 31.1 months, p?=?0.181). Receptor conversion in BCBMs was observed in over 50% of Korean patients used in this study. HER2 conversion was observed in 23.8% of patients in this study. Therefore, if resistance to anti-HER2 treatment is suspected in patients with BCBM, biopsy is needed to determine receptor profiles of brain lesion. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|